Theriva Biologics (TOVX) Accumulated Expenses (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Accumulated Expenses of $205000.0 for Q1 2026, down 12.39% year-over-year from $234000.0 in Q1 2025, and up 376.74% quarter-over-quarter from $43000.0 in Q4 2025.
Theriva Biologics (TOVX) Accumulated Expenses (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Accumulated Expenses for 17 consecutive years, with $205000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 12.39% year-over-year to $205000.0; the TTM figure through Mar 2026 stood at $205000.0 (down 12.39% YoY), while the FY2025 annual figure was $43000.0, down 98.72% from the prior year.
- Accumulated Expenses improved to $205000.0 in Q1 2026 per TOVX's latest filing, from $43000.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $3.5 million in Q2 2024 and bottomed at $43000.0 in Q4 2025.
- Historically, Accumulated Expenses has averaged $808117.6 across 5 years, with a median of $206000.0 in 2023.
- Annual changes were most pronounced in 2024 — Accumulated Expenses surged 2960.53% — and 2025, when it tumbled 98.72%.
- Theriva Biologics' Accumulated Expenses stood at $100000.0 in 2022, then advanced by 27.0% to $127000.0 in 2023, then soared by 2551.97% to $3.4 million in 2024, then sank by 98.72% to $43000.0 in 2025, then soared by 376.74% to $205000.0 in 2026.
- Business Quant data shows TOVX's Accumulated Expenses at $205000.0 in Q1 2026, $43000.0 in Q4 2025, and $131000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.42 Mn |
| Mar 31, 2026 | 205,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Sep 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 759,000.00 |
| Mar 31, 2025 | 234,000.00 |
| Dec 31, 2024 | 3.37 Mn |
| Sep 30, 2024 | 982,000.00 |
| Jun 30, 2024 | 3.49 Mn |
| Mar 31, 2024 | 325,000.00 |
| Dec 31, 2023 | 127,000.00 |
| Sep 30, 2023 | 206,000.00 |
| Jun 30, 2023 | 114,000.00 |
| Mar 31, 2023 | 142,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Sep 30, 2022 | 1.41 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | 115,000.00 |
| Dec 31, 2021 | 700,000.00 |
| Sep 30, 2021 | 1.01 Mn |